Chen Chen

Chen Chen

Auto-generated profile, based on publicly available information

Chen Chen

Verily Life Sciences, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
MBMaximilien Burq
Maximilien Burq
ERErin Rainaldi
Erin Rainaldi
KHKing Chung Ho
King Chung Ho
CCChen Chen
Chen Chen
BBBastiaan R. Bloem
Bastiaan R. Bloem
RKRitu Kapur
Ritu Kapur
Sensor-based remote monitoring could help better track Parkinson’s disease (PD) progression, and measure patients’ response to putative disease-modifying therapeutic interventions. To be useful, the remotely-collected measurements should be valid, reliable, and sensitive to change, and people with PD must engage with the technology. We developed a smartwatch-based active assessment that enables unsupervised measurement of motor signs of PD. Participants with early-stage PD (N = 388, 64% men, average age 63) wore a smartwatch for a median of 390 days. Participants performed unsupervised motor tasks both in-clinic (once) and remotely (twice weekly for one year). Dropout rate was 5.4%. Median wear-time was 21.1 h/day, and 59% of per-protocol remote assessments were completed. Analytical validation was established for in-clinic measurements, which showed moderate-to-strong correlations with consensus MDS-UPDRS Part III ratings for rest tremor (⍴ = 0.70), bradykinesia (⍴ = −0.62), and gait (⍴ = −0.46). Test-retest reliability of remote measurements, aggregated monthly, was good-to-excellent (ICC = 0.75–0.96). Remote measurements were sensitive to the known effects of dopaminergic medication (on vs off Cohen’s d = 0.19–0.54). Of note, in-clinic assessments often did not reflect the patients’ typical status at home. This demonstrates the feasibility of smartwatch-based unsupervised active tests, and establishes the analytical validity of associated digital measurements. Weekly measurements provide a real-life distribution of disease severity, as it fluctuates longitudinally. Sensitivity to medication-induced change and improved reliability imply that these methods could help reduce sample sizes needed to demonstrate a response to therapeutic interventions or disease progression.

10 October 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SSSanidhya Singh
Sanidhya Singh
MBMiles Romney Bennett
Miles Romney Bennett
CCChen Chen
Chen Chen
SSSooyoon Shin
Sooyoon Shin
HGHamid Ghanbari
Hamid Ghanbari
BNBenjamin W Nelson
Benjamin W Nelson
Background: Photoplethysmography (PPG) is a technology routinely used in clinical practice to assess blood oxygenation (SpO2) and pulse rate (PR). Skin pigmentation may influence accuracy, leading to health outcomes disparities. Objective: This systematic review and meta-analysis primarily aimed to evaluate the accuracy of PPG-derived SpO2 and PR by skin pigmentation. Secondarily, we aimed to evaluate statistical biases and the clinical relevance of PPG-derived SpO2 and PR according to skin pigmentation. Methods: We identified 23 pulse oximetry studies (n=59,684; 197,353 paired SpO2-arterial blood observations) and 4 wearable PR studies (n=176; 140,771 paired PPG-electrocardiography observations). We evaluated accuracy according to skin pigmentation group by comparing SpO2 accuracy root-mean-square values to the regulatory threshold of 3% and PR 95% limits of agreement values to +5 or –5 beats per minute (bpm), according to the standards of the American National Standards Institute, Association for the Advancement of Medical Instrumentation, and the International Electrotechnical Commission. We evaluated biases and clinical relevance using mean bias and 95% CI. Results: For SpO2, accuracy root-mean-square values were 3.96%, 4.71%, and 4.15%, and pooled mean biases were 0.70% (95% CI 0.17%-1.22%), 0.27% (95% CI –0.64% to 1.19%), and 1.27% (95% CI 0.58%-1.95%) for light, medium, and dark pigmentation, respectively. For PR, 95% limits of agreement values were from –16.02 to 13.54, from –18.62 to 16.84, and from –33.69 to 32.54, and pooled mean biases were –1.24 (95% CI –5.31 to 2.83) bpm, –0.89 (95% CI –3.70 to 1.93) bpm, and –0.57 (95% CI –9.44 to 8.29) bpm for light, medium, and dark pigmentation, respectively. Conclusions: SpO2 and PR measurements may be inaccurate across all skin pigmentation groups, breaching U.S. Food and Drug Administration guidance and industry standard thresholds. Pulse oximeters significantly overestimate SpO2 for both light and dark skin pigmentation, but this overestimation may not be clinically relevant. PRs obtained from wearables exhibit no statistically or clinically significant bias based on skin pigmentation.

3 March 2023 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
CCChen Chen
Chen Chen
NKNathan R. Kowahl
Nathan R. Kowahl
ERErin Rainaldi
Erin Rainaldi
MBMaximilien Burq
Maximilien Burq
LMLeanne Munsie
Leanne Munsie
RKRitu Kapur
Ritu Kapur
Few late-stage clinical trials in Parkinson's disease (PD) have produced evidence on the clinical validity of sensor-based digital measurements of daily life activities to detect responses to treatment. The objective of this study was to assess whether digital measures from patients with mild-to-moderate Lewy Body Dementia demonstrate treatment effects during a randomized Phase 2 trial. Substudy within a 12-week trial of mevidalen (placebo vs 10, 30, or 75 mg), where 70/344 patients (comparable to the overall population) wore a wrist-worn multi-sensor device. Treatment effects were statistically significant by conventional clinical assessments (Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS] sum of Parts I-III and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change [ADCS-CGIC] scores) in the full study cohort at Week 12, but not in the substudy. However, digital measurements detected significant effects in the substudy cohort at week 6, persisting to week 12. Digital measurements detected treatment effects in a smaller cohort over a shorter period than conventional clinical assessments. clinicaltrials.gov, NCT03305809.

28 December 2022 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
MBMaximilien Burq
Maximilien Burq
ERErin Rainaldi
Erin Rainaldi
KHKing Chung Ho
King Chung Ho
CCChen Chen
Chen Chen
BBBastiaan R. Bloem
Bastiaan R. Bloem
RKRitu Kapur
Ritu Kapur
The Code/Materials statement is amended to 'The code used in the study is proprietary, and will not be made available. We direct readers to the data availability section on applications for data use as a qualified researcher.' The original article has been corrected.

24 February 2021 in Computational Statistics
Verified
Journal Article
Closed access
PDF file
PCPatrick Coyle
Patrick Coyle
CCChen Chen
Chen Chen
NDNooreen Dabbish
Nooreen Dabbish

4 June 2024 in JMIR Preprints
Verified
Preprint
Open access
SSSanidhya Singh
Sanidhya Singh
MBMiles Romney Bennett
Miles Romney Bennett
CCChen Chen
Chen Chen
SSSooyoon Shin
Sooyoon Shin
HGHamid Ghanbari
Hamid Ghanbari
BNBenjamin W Nelson
Benjamin W Nelson
BACKGROUND Photoplethysmography (PPG) is a technology routinely used in clinical practice to assess blood oxygenation (SpO2) and pulse rate (PR). Skin pigmentation may influence accuracy, leading to health outcomes disparities. OBJECTIVE This systematic review and meta-analysis primarily aimed to evaluate the accuracy of PPG-derived SpO2 and PR by skin pigmentation. Secondarily, we aimed to evaluate statistical biases and the clinical relevance of PPG-derived SpO2 and PR according to skin pigmentation. METHODS We identified 23 pulse oximetry studies (n=59,684; 197,353 paired SpO2-arterial blood observations) and 4 wearable PR studies (n=176; 140,771 paired PPG-electrocardiography observations). We evaluated accuracy according to skin pigmentation group by comparing SpO2 accuracy root-mean-square values to the regulatory threshold of 3% and PR 95% limits of agreement values to +5 or –5 beats per minute (bpm), according to the standards of the American National Standards Institute, Association for the Advancement of Medical Instrumentation, and the International Electrotechnical Commission. We evaluated biases and clinical relevance using mean bias and 95% CI. RESULTS For SpO2, accuracy root-mean-square values were 3.96%, 4.71%, and 4.15%, and pooled mean biases were 0.70% (95% CI 0.17%-1.22%), 0.27% (95% CI –0.64% to 1.19%), and 1.27% (95% CI 0.58%-1.95%) for light, medium, and dark pigmentation, respectively. For PR, 95% limits of agreement values were from –16.02 to 13.54, from –18.62 to 16.84, and from –33.69 to 32.54, and pooled mean biases were –1.24 (95% CI –5.31 to 2.83) bpm, –0.89 (95% CI –3.70 to 1.93) bpm, and –0.57 (95% CI –9.44 to 8.29) bpm for light, medium, and dark pigmentation, respectively. CONCLUSIONS SpO2 and PR measurements may be inaccurate across all skin pigmentation groups, breaching U.S. Food and Drug Administration guidance and industry standard thresholds. Pulse oximeters significantly overestimate SpO2 for both light and dark skin pigmentation, but this overestimation may not be clinically relevant. PRs obtained from wearables exhibit no statistically or clinically significant bias based on skin pigmentation.